Dopamine selectively sensitizes dopaminergic neurons to rotenone-induced apoptosis.

Ferogh A Ahmadi, Tom N Grammatopoulos, Andy M Poczobutt, Susan M Jones, Laurence D Snell, Mita Das, W Michael Zawada
Author Information
  1. Ferogh A Ahmadi: Division of Clinical Pharmacology and Toxicology, Department of Medicine, University of Colorado at Denver and Health Sciences Center, Denver, CO 80262, USA.

Abstract

Among various types of neurons affected in Parkinson's disease, dopamine (DA) neurons of the substantia nigra undergo the most pronounced degeneration. Products of DA oxidation and consequent cellular damage have been hypothesized to contribute to neuronal death. To examine whether elevated intracellular DA will selectively predispose the dopaminergic subpopulation of nigral neurons to damage by an oxidative insult, we first cultured rat primary mesencephalic cells in the presence of rotenone to elevate reactive oxygen species. Although MAP2(+) neurons were more sensitive to rotenone-induced toxicity than type 1 astrocytes, rotenone affected equally both DA (TH(+)) neurons and MAP2(+) neurons. In contrast, when intracellular DA concentration was elevated, DA neurons became selectively sensitized to rotenone. Raising intracellular DA levels in primary DA neurons resulted in dopaminergic neuron death in the presence of subtoxic concentrations of rotenone. Furthermore, mitochondrial superoxide dismutase mimetic, manganese (III) meso-tetrakis (4-benzoic acid) porphyrin, blocked activation of caspase-3, and consequent cell death. Our results demonstrate that an inhibitor of mitochondrial complex I and increased cytosolic DA may cooperatively lead to conditions of elevated oxidative stress and thereby promote selective demise of dopaminergic neurons.

References

  1. Acta Pharmacol Sin. 2005 Jan;26(1):17-26 [PMID: 15659109]
  2. Antioxid Redox Signal. 2005 May-Jun;7(5-6):630-8 [PMID: 15890007]
  3. Cell Transplant. 1999 Jan-Feb;8(1):25-36 [PMID: 10338273]
  4. Brain Res. 1990 Sep 3;526(2):303-7 [PMID: 2257487]
  5. Biochem Soc Trans. 2006 Feb;34(Pt 1):88-90 [PMID: 16417489]
  6. J Neurosci. 2006 Sep 6;26(36):9304-11 [PMID: 16957086]
  7. Brain Res. 2000 Dec 8;885(2):283-8 [PMID: 11102582]
  8. J Neurol Sci. 1991 Aug;104(2):203-8 [PMID: 1658241]
  9. Neurobiol Dis. 2007 Jan;25(1):112-20 [PMID: 17049260]
  10. Neurosci Lett. 1994 Mar 14;169(1-2):126-8 [PMID: 8047266]
  11. J Neurosci. 2006 Sep 27;26(39):10068-78 [PMID: 17005870]
  12. Proc Natl Acad Sci U S A. 1989 Feb;86(4):1398-400 [PMID: 2919185]
  13. Arch Biochem Biophys. 1996 Apr 15;328(2):309-16 [PMID: 8645009]
  14. Neuropharmacology. 2000 Apr 3;39(6):1016-20 [PMID: 10727711]
  15. Nat Neurosci. 2000 Dec;3(12):1301-6 [PMID: 11100151]
  16. Biochem Pharmacol. 1996 Feb 9;51(3):267-73 [PMID: 8573193]
  17. Chem Biol Interact. 1989;72(3):309-24 [PMID: 2557982]
  18. J Neurochem. 1994 Sep;63(3):910-6 [PMID: 7519665]
  19. J Neurochem. 2003 Sep;86(6):1338-45 [PMID: 12950443]
  20. J Neural Transm Suppl. 2003;(65):89-100 [PMID: 12946051]
  21. J Neurochem. 2001 Feb;76(3):745-9 [PMID: 11158245]
  22. Stem Cells. 2006 Sep;24(9):2110-9 [PMID: 16728559]
  23. J Cereb Blood Flow Metab. 2002 Feb;22(2):232-9 [PMID: 11823721]
  24. J Neurochem. 2000 Dec;75(6):2611-21 [PMID: 11080215]
  25. J Neurochem. 2003 Jan;84(1):112-8 [PMID: 12485407]
  26. Brain Res. 1997 Nov 28;777(1-2):110-8 [PMID: 9449419]
  27. FEBS Lett. 1996 Feb 26;381(1-2):82-6 [PMID: 8641445]
  28. Lancet. 1989 Jul 1;2(8653):49 [PMID: 2567823]
  29. Immunology. 1998 Jul;94(3):345-55 [PMID: 9767416]
  30. Ann Neurol. 1989 Dec;26(6):719-23 [PMID: 2557792]
  31. Int J Epidemiol. 2000 Apr;29(2):323-9 [PMID: 10817132]
  32. Antioxid Redox Signal. 2005 May-Jun;7(5-6):662-72 [PMID: 15890011]
  33. J Neurosci. 2005 Oct 12;25(41):9428-33 [PMID: 16221852]
  34. J Neurosci. 1999 Feb 15;19(4):1484-91 [PMID: 9952424]
  35. Biochem Biophys Res Commun. 1989 Sep 29;163(3):1450-5 [PMID: 2551290]
  36. J Neurochem. 1990 Mar;54(3):823-7 [PMID: 2154550]
  37. Toxicol Lett. 2002 Jun 14;132(2):83-93 [PMID: 12044541]
  38. J Neurosci. 2000 Dec 15;20(24):9207-14 [PMID: 11124998]
  39. Eur J Pharmacol. 1995 Jul 14;280(3):251-6 [PMID: 8566093]
  40. Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7659-63 [PMID: 9636206]
  41. Brain Res. 2004 May 29;1009(1-2):9-16 [PMID: 15120578]
  42. Mol Pharmacol. 1978 Jul;14(4):633-43 [PMID: 98706]
  43. J Neurochem. 1995 Feb;64(2):936-9 [PMID: 7530297]
  44. Exp Neurol. 2003 Jan;179(1):9-16 [PMID: 12504863]
  45. Neuroreport. 2003 Dec 19;14(18):2425-8 [PMID: 14663204]
  46. J Exp Biol. 2004 Aug;207(Pt 18):3221-31 [PMID: 15299043]
  47. Exp Neurol. 2004 Apr;186(2):235-41 [PMID: 15026259]
  48. J Neurochem. 1999 Dec;73(6):2546-54 [PMID: 10582617]
  49. Nat Med. 1996 Sep;2(9):1017-21 [PMID: 8782460]
  50. Ann Neurol. 2003;53 Suppl 3:S61-70; discussion S70-2 [PMID: 12666099]
  51. J Neurochem. 2003 Nov;87(4):914-21 [PMID: 14622122]
  52. Neurology. 1996 Dec;47(6 Suppl 3):S161-70 [PMID: 8959985]
  53. Annu Rev Neurosci. 1997;20:125-56 [PMID: 9056710]
  54. Neurotox Res. 2000 Feb;1(3):181-95 [PMID: 12835101]
  55. Science. 1998 Aug 28;281(5381):1312-6 [PMID: 9721091]
  56. Eur J Pharmacol. 2003 Jul 4;472(1-2):81-7 [PMID: 12860476]
  57. Ann N Y Acad Sci. 1992 May 11;648:42-62 [PMID: 1353337]
  58. Nitric Oxide. 1997 Jun;1(3):234-43 [PMID: 9704585]
  59. Neuron. 2005 Aug 4;47(3):365-78 [PMID: 16055061]
  60. Can J Neurol Sci. 1987 Aug;14(3 Suppl):414-8 [PMID: 3676917]
  61. Am J Physiol. 1998 Apr;274(4):C855-60 [PMID: 9575780]
  62. J Mol Cell Cardiol. 1997 Jun;29(6):1731-8 [PMID: 9220358]

Grants

  1. NS 38619/NINDS NIH HHS
  2. U01 AA13473/NIAAA NIH HHS

MeSH Term

Animals
Apoptosis
Dopamine
Glial Fibrillary Acidic Protein
Immunohistochemistry
Neurons
Oxidative Stress
Rats
Rats, Sprague-Dawley
Rotenone

Chemicals

Glial Fibrillary Acidic Protein
Rotenone
Dopamine

Word Cloud

Created with Highcharts 10.0.0neuronsDAdopaminergicrotenonedeathelevatedintracellularselectively+affectedconsequentdamageoxidativeprimarypresenceMAP2rotenone-inducedmitochondrialAmongvarioustypesParkinson'sdiseasedopaminesubstantianigraundergopronounceddegenerationProductsoxidationcellularhypothesizedcontributeneuronalexaminewhetherwillpredisposesubpopulationnigralinsultfirstculturedratmesencephaliccellselevatereactiveoxygenspeciesAlthoughsensitivetoxicitytype1astrocytesequallyTHcontrastconcentrationbecamesensitizedRaisinglevelsresultedneuronsubtoxicconcentrationsFurthermoresuperoxidedismutasemimeticmanganeseIIImeso-tetrakis4-benzoicacidporphyrinblockedactivationcaspase-3cellresultsdemonstrateinhibitorcomplexincreasedcytosolicmaycooperativelyleadconditionsstresstherebypromoteselectivedemiseDopaminesensitizesapoptosis

Similar Articles

Cited By